Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Daiichi Sankyo
Teva
Covington
Boehringer Ingelheim
Federal Trade Commission
Fish and Richardson
Fuji
Healthtrust
Merck

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204165

« Back to Dashboard
NDA 204165 describes CLOPIDOGREL BISULFATE, which is a drug marketed by Acme Labs, Actavis Totowa, Gate Pharms, Dr Reddys Labs Ltd, Accord Hlthcare, Teva Pharms, Macleods Pharms Ltd, Sun Pharm Inds, Aurobindo Pharma Ltd, Torrent Pharms Ltd, Amneal Pharms, Cspc Ouyi Pharm Co, Mylan Pharms Inc, Sciegen Pharms Inc, Wockhardt Ltd, Dr Reddys Labs Inc, Apotex Inc, Zydus Pharms Usa Inc, Sun Pharma Global, and Teva, and is included in twenty NDAs. It is available from forty-seven suppliers. Additional details are available on the CLOPIDOGREL BISULFATE profile page.

The generic ingredient in CLOPIDOGREL BISULFATE is clopidogrel bisulfate. There are fifty-three drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the clopidogrel bisulfate profile page.

Summary for NDA: 204165

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Blood Products/Modifiers/ Volume Expanders
Formulation / Manufacturing:see details

Pharmacology for NDA: 204165

Suppliers and Packaging for NDA: 204165

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CLOPIDOGREL BISULFATE
clopidogrel bisulfate
TABLET;ORAL 204165 ANDA Camber Pharmaceuticals, Inc. 31722-901 31722-901-01 100 TABLET, FILM COATED in 1 BOTTLE (31722-901-01)
CLOPIDOGREL BISULFATE
clopidogrel bisulfate
TABLET;ORAL 204165 ANDA Camber Pharmaceuticals, Inc. 31722-901 31722-901-05 500 TABLET, FILM COATED in 1 BOTTLE (31722-901-05)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 75MG BASE
Approval Date:Sep 15, 2014TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 300MG BASE
Approval Date:Sep 15, 2014TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Express Scripts
Cerilliant
Novartis
Colorcon
UBS
Chubb
Daiichi Sankyo
Farmers Insurance
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot